
A pilot study found that immune checkpoint inhibitors (ICIs) significantly reduced actinic keratoses (AKs) and keratinocyte carcinomas (KCs) in cancer patients. The mean AK count dropped from 47.2 to 14.3 over 12 months, and KC incidence also declined. These findings suggest a potential immunopreventive role for ICIs in managing field cancerization in high-risk individuals.
Like
Save
Share